AGENNIX, INC.

Company Information

Company Name
AGENNIX, INC.
Address
AGENNIX, INC.
8 GREENWAY PLZ, STE 910
HOUSTON, TX, 77046 0892
Phone
n/a
URL
n/a
DUNS
808956700
Number of Employees
n/a
Hubzone Owned

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,908,936.00
7
SBIR Phase II
$4,498,960.00
4
STTR Phase I
$221,691.00
3
STTR Phase II
$274,703.00
1
Chart code to be here

Award List

  1. N/A

    Amount: $100,733.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  2. THERAPY FOR GASTROINTESTINAL DISORDERS

    Amount: $105,891.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  3. Therapy for gastrointestinal disorders

    Amount: $0.00

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) ...

    STTR Phase I 2001 Department of Health and Human Services
  4. Therapy for gastrointestinal disorders

    Amount: $274,703.00

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) ...

    STTR Phase II 2001 Department of Health and Human Services
  5. Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

    Amount: $100,035.00

    DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing ...

    SBIR Phase I 2003 Department of Health and Human Services
  6. Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

    Amount: $715,265.00

    DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing ...

    SBIR Phase II 2004 Department of Health and Human Services
  7. Recombinant human lactoferrin to treat oral mucositis

    Amount: $349,929.00

    DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause ...

    SBIR Phase I 2004 Department of Health and Human Services
  8. Lactoferrin in Primate and Mouse Models of Asthma

    Amount: $99,925.00

    DESCRIPTION (provided by applicant): The purpose of this research is to extend work to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in an established primate mode ...

    SBIR Phase I 2004 Department of Health and Human Services
  9. Phase II Clinical Trial of Lactoferrin in Asthma

    Amount: $749,920.00

    DESCRIPTION (provided by applicant): The purpose of this research is to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in Phase II clinical trials in patients with ...

    SBIR Phase II 2005 Department of Health and Human Services
  10. Recombinant Lactoferrin and Necrotizing Enterocolitis

    Amount: $115,800.00

    DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC ...

    STTR Phase I 2004 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government